Man Group
MRSN

Man Group’s Mersana Therapeutics MRSN Stock Holding History

Man Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,784
Closed -$103K – 2220
2023
Q4 		$103K Buy
+1,784
New +$71.8K ﹤0.01% 1982
2023
Q2 		– Hold
0
– -$103K – 2128
2023
Q1 		– Sell
-639
Closed -$89.7K – 1965
2022
Q4 		$93.5K Buy
+639
New +$108K ﹤0.01% 1917
2022
Q2 		– Sell
-2,280
Closed -$227K – 2289
2022
Q1 		$227K Buy
+2,280
New +$266K ﹤0.01% 1893

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return